Abliva to participate in World Mitochondrial Disease Week 2021

2021-09-17 11:00:00

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will participate in World Mitochondrial Disease Week through videos that will be released on Abliva’s website daily during the week, 19 – 25 September.

The videos will be focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases (PMDs). Over the week we will highlight the huge unmet medical need in the area and discuss Abliva’s own efforts to treat mitochondrial disease patients with our two clinical stage compounds.

Starting 19 September, Abliva’s videos will be posted daily on https://abliva.com/poster/presentationer/world-mitochondrial-disease-week-2021/ as well as on the company’s YouTube channel and LinkedIn page.

World Mitochondrial Disease Week is an initiative of International Mito Patients (IMP). The purpose of the World Mitochondrial Disease Week is to raise awareness of mitochondrial disease (mito) on a global scale through educational, fundraising and advocacy activities.
https://mitochondrialdiseaseweek.org

MFN